AI and Tariffs Under Siege: How Can Taiwan's Biotech Industry Break the Impasse? (1)-Corporate culture.

AI and Tariffs Under Siege: How Can Taiwan's Biotech Industry Break the Impasse? (1)-Corporate culture.
The global biotech market continues its growth trajectory, projected to rise from US$483 billion in 2024 to US$546 billion in 2025, marking a substantial annual increase of 13%. Taiwan has also been continuously promoting the development of its biotech industry since the "5+2 Industrial Innovation Program," hoping it will become a new engine for economic growth. However, facing the multiple pressures of international competition, the AI wave, and tariff policies, Taiwan's biotech industry will encounter significant challenges in the next five years.
For a long time, foreign companies, leveraging advantages such as higher salaries, transparent systems, and talent internationalization, have exerted a strong attraction on local biotech talent. A former senior executive of an American pharmaceutical company pointed out in an interview that foreign companies adopt flat management structures, open communication, and internal job posting systems, encouraging employees to actively pursue promotions and learning opportunities, thereby building elite teams of strong individuals. In contrast, some Taiwanese local companies still follow Japanese-style culture, characterized by distinct hierarchies and a greater tendency towards management by individuals. Coupled with salary and benefits that may not align with foreign standards, their attractiveness to high-level talent or overseas talent returning to Taiwan is relatively limited.